Evommune reports $290 million in cash, funding its pipeline through the second half of 29. Its 330-patient oral migraine trial reads out in the second half of 2027.
EVMN · Evommune, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 61%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Nov 2025 to Nov 2026
Latest documents
Evommune approved cash retention awards for its Chief Executive Officer, Chief Financial Officer, and Chief Business & Legal Officer, and repriced underwater stock options to $7.63 per share, covering 3,692,840 shares.
Evommune discontinued EVO756 development in CSU and AD after Phase 2b trials missed endpoints, while migraine development continues. It reported $262.3 million in liquidity and expects funding into the second half of 2029.
Evommune licensed EVO570 from Hinova for $30 million upfront and raised approximately $30 million through a private placement, reporting $262.3 million in cash, cash equivalents and investments and cash runway into 2H 2029.
Evommune made a pre-recorded webcast available at 8:30 a.m. ET on November 5, 2026, covering EVO570’s preclinical profile, planned rheumatoid arthritis development path and Hinova Pharmaceuticals Inc. license terms.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| least-squares mean reduction from baseline in Eczema Area and Severity Index (EASI) | 55% | Week 12 | — |
| patients achieved vIGA 0/1 | 23% | week 12 | — |
| patients achieved vIGA 0/1 on placebo | 0% | week 12 | — |
| placebo-adjusted EASI improvement | 34% | week 8 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EVMN
this stock
Evommune, Inc.
|
$291.10M | -58.9% | +85.7% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 28
Evommune reports $290 million in cash, funding its pipeline through the second half of 29. Its 330-patient oral migraine trial reads out in the second half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EVMN | -7.7% | +38.0% | -64.5% | +4.6% | -58.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.8% | +47.3% | -55.3% | +13.3% | -60.0% |